Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1892-1903

  Vesikari, Timo ^a   Forstén, Aino ^a   Boutriau, Dominique ^b   Bianco, Véronique ^b   Van Der Wielen, Marie ^b   Miller, Jacqueline ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b GSK   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Bactericidal activity; Conjugate vaccine; Persistence; Safety; Tetravalent meningococcal vaccine; Toddler

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; MENINGOCOCCUS TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FEVER; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; IRRITABILITY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RISK ASSESSMENT; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; TREATMENT OUTCOME; VACCINATION REACTION;

BACTERICIDAL ACTIVITY; CONJUGATE VACCINE; PERSISTENCE; SAFETY; TETRAVALENT MENINGOCOCCAL VACCINE; TODDLER;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; TIME FACTORS;

EID: 84872235709     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22166     Document Type: Article

References (61)

1. Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286:694-9; PMID:11495619; http://dx.doi.org/10.1001/jama.286.6.694.
2. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23(Suppl):S274-9; PMID:15597069.
3. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36; PMID:17168995; http://dx.doi.org/10.1111/j.1574-6976.2006.00060. x.
4. Centers for Disease Control and Prevention. Summary of Notifiable Diseases - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:39-40.
5. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063.
6. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981; 99:540-5; PMID:7277093; http://dx.doi.org/10.1016/S0022-3476(81)80250-8.
7. Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr Infect Dis J 2011; 30:3-6; PMID:20683377; http://dx.doi.org/10.1097/INF.0b013e3181ef25f7.
8. Delrieu I, Yaro S, Tamekloé TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE 2011; 6:e19513; PMID:21625480; http://dx.doi.org/10.1371/journal.pone.0019513.
9. Boisier P, Djibo S, Sidikou F, Mindadou H, Kairo KK, Djibo A, et al. Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135. Trop Med Int Health 2005; 10:435-43; PMID:15860090; http://dx.doi.org/10.1111/j.1365-3156.2005.01394.x.
10. Djibo S, Nicolas P, Alonso J-M, Djibo A, Couret D, Riou J-Y, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003; 8:1118-23; PMID:14641847; http://dx.doi.org/10.1046/j.1360- 2276.2003.01126.x.
11. Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, Kriz P, et al. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 2002; 8:462-6; PMID:11996679; http://dx.doi.org/10.3201/eid0805.010227.
12. European Centre for Disease Prevention and Control. Annual epidemiological report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm ECDC 2011; 155-157.
13. Tsolia MN, Theodoridou M, Tzanakaki G, Vlachou V, Mostrou G, Stripeli F, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006; 25:449-56; PMID:16773393; http://dx.doi.org/10.1007/ s10096-006-0155-6.
14. Hedberg ST, Törös B, Fredlund H, Olcén P, Mölling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011; 16:19885; PMID:21679677.
15. Kriz P, Wieffer H, Holl K, Rosenlund M, Budhia S, Vyse A. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Rev Vaccines 2011; 10:1477-86; PMID:21988310; http://dx.doi.org/10.1586/erv.11.117.
16. Caugant DA, Løvoll Ø, Blystad H. Meningococcal disease in Norway, 2009-2010: emergence of serogroup Y [Abstract P040]. In: 11th Meeting of the European Monitoring Group on Meningococci (EMGM), Ljubljana, Slovenia, May 18 to 20, 2011.
17. Ladhani S, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Investigations into an increase in reported meningococcal serogroup Y disease in England and Wales in 2007-9 [Abstract P035]. In: 11th Meeting of the European Monitoring Group on Meningococci (EMGM), Ljubljana, Slovenia, May 18 to 20, 2011.
18. Trotter C, Findlow H, Chadha H, Townsend K, Thompson D, Mabey L, et al. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009 [Abstract P036]. In: 11th Meeting of the European Monitoring Group on Meningococci (EMGM), Ljubljana, Slovenia, May 18 to 20, 2011.
19. Antignac A, Ducos-Galand M, Guiyoule A, Pirès R, Alonso J-M, Taha M-K. Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis 2003; 37:912-20; PMID:13130402; http://dx.doi.org/10.1086/377739.
20. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al.; Meningococcal Reference Unit. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96; PMID:16772416; http://dx.doi.org/10.1099/jmm.0.46288-0.
21. Hsueh P-R, Teng L-J, Lin T-Y, Chen K-T, Hsu H-M, Twu S-J, et al. Re-emergence of meningococcal disease in Taiwan: circulation of domestic clones of Neisseria meningitidis in the 2001 outbreak. Epidemiol Infect 2004; 132:637-45; PMID:15310165; http://dx.doi.org/10.1017/S0950268804002316.
22. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54(RR-7):1-21; PMID:15917737.
23. Reisinger KS, Black S, Stoddard JJ. Optimizing protection against meningococcal disease. Clin Pediatr (Phila) 2010; 49:586-97; PMID:20089551; http://dx.doi.org/10.1177/0009922809354327.
24. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142-64; PMID:16418528; http://dx.doi.org/10.1128/ CMR.19.1.142-164.2006.
25. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7; PMID:15276396; http://dx.doi.org/10.1016/S0140-6736(04) 16725-1.
26. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09.
27. de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE 2010; 5:e12144; PMID:20730091; http://dx.doi.org/10.1371/ journal.pone.0012144.
28. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006; 5:269-75; PMID:16608426; http://dx.doi.org/10.1586/14760584.5.2.269.
29. Larrauri A, Cano R, García M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 23:4097-100; PMID:15908059; http://dx.doi.org/10.1016/j.vaccine.2005.03. 045.
30. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009; 27(Suppl 2):B30-41; PMID:19477560; http://dx.doi.org/10. 1016/j.vaccine.2009.05.003.
31. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62; PMID:15665711; http://dx.doi.org/10.1097/01.inf. 0000148928.10057.86.
32. Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 2010; 29:259-67; PMID:20033465; http://dx.doi.org/10.1007/ s10096-009-0848-8.
33. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9.
34. Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068.
35. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53; PMID:19887137; http://dx.doi.org/10.1016/j. vaccine.2009.10.064.
36. Östergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075.
37. Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/ INF.0b013e31820e6e02.
38. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965; http://dx.doi.org/10.1016/j.vaccine. 2011.03.043.
39. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009.
40. Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis 2012; 16:e608-15; PMID:22704725; http://dx.doi.org/10.1016/j.ijid. 2012.04.006.
41. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657-63; PMID:19895922; http://dx.doi.org/10.1016/j.vaccine.2009.10.104.
42. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13; PMID:16203934; http://dx.doi.org/10.1001/archpedi.159.10.907.
43. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28:86-91; PMID:19116603; http://dx.doi.org/10.1097/ INF.0b013e31818a0237.
44. Glode MP, Robbins JB, Liu TY, Gotschlich EC, Orskov I, Orskov F. Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 1977; 135:94-104; PMID:64575; http://dx.doi.org/10.1093/infdis/135.1.94.
45. Guirguis N, Schneerson R, Bax A, Egan W, Robbins JB, Shiloach J, et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med 1985; 162:1837-51; PMID:3934317; http://dx.doi.org/10.1084/jem.162.6.1837.
46. Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, et al.; HibMenCY-TT 005 Study Group. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48-52; PMID:20035207; http://dx.doi.org/10.1097/INF.0b013e3181c3ce88.
47. Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, et al. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2011; 30:190-6; PMID:20948453; http://dx.doi.org/10.1097/INF.0b013e3181fcb2bf.
48. Troncoso G, Sánchez S, Criado MT, Ferreirós CM. Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis. FEMS Immunol Med Microbiol 2002; 34:9-15; PMID:12208601; http://dx.doi.org/10.1111/j.1574-695X.2002.tb00597.x.
49. Plested JS, Welsch JA, Granoff DM. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 2009; 16:785-91; PMID:19339487; http://dx.doi.org/10.1128/CVI.00007-09.
50. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009; 77:764-9; PMID:19047406; http://dx.doi.org/10.1128/IAI.01191-08.
51. Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Ubeda-Sansano I, Jubert-Rosich A, Puig-Barbera J, et al. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J 2010; 29:768-70; PMID:20375851; http://dx.doi.org/10.1097/ INF.0b013e3181d9e653.
52. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-9; PMID:19906895; http://dx.doi.org/10.1128/CVI.00384-09.
53. Díez-Domingo J, Cantarino MV, Torrentí JM, Sansano MI, Rosich AJ, Merino AH, et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 2010; 29:148-52; PMID:19927040; http://dx.doi.org/10.1097/INF. 0b013e3181b9a831.
54. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3; PMID:11078484; http://dx.doi.org/10.1086/317646.
55. Gill CJ, Baxter R, Anemona A, Ciavarro GL, Dull PM. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881-7; PMID:21339701; http://dx.doi.org/10.4161/ hv.6.11.12849.
56. Poolman JT, De Vleeschauwer I, Durant N, Devos N, Feron C, Lestrate P, et al. Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay. Clin Vaccine Immunol 2011; 18:1108-17; PMID:21593240; http://dx.doi.org/10.1128/CVI.00549-10.
57. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904.
58. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051.
59. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09.
60. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307.
61. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al.; The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649.